Associated tags: TSX, Patient, Pharmaceutical industry, Methotrexate, Hematopoietic stem cell transplantation, Hematology, Customer service, Blood, Treosulfan, Rheumatoid arthritis, Allergy, Health Canada, FDA, Collaboration, World Health Organization, Glioma
TORONTO and CHICAGO, April 18, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce that company management will be participating in the 2023 Bloom Burton & Co. Healthcare Investor Conference from April 25 to 26, 2023.
Key Points:
- TORONTO and CHICAGO, April 18, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce that company management will be participating in the 2023 Bloom Burton & Co. Healthcare Investor Conference from April 25 to 26, 2023.
- Event: 2023 Bloom Burton & Co. Healthcare Investor Conference
Ken d’Entremont, Medexus’s Chief Executive Officer, and Marcel Konrad, Medexus’s Chief Financial Officer, will deliver a presentation on April 25, 2023 at 9:30 AM Eastern time and will be available for in-person one-on-one meetings throughout the conference.
- A live and recorded webcast of the Medexus presentation will be available on the Investors—News & Events section of Medexus’s corporate website or at the following link:
BMO,
Maintenance,
Marketing,
Patient,
TSX,
Growth,
MDP,
News,
Tobacco,
Fine chemical,
Audit TORONTO and CHICAGO, April 11, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce preliminary revenue estimates for the company’s fourth fiscal quarter and full fiscal year ended March 31, 2023, and, in addition, is providing an additional business update to shareholders and other stakeholders.
Key Points:
- TORONTO and CHICAGO, April 11, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce preliminary revenue estimates for the company’s fourth fiscal quarter and full fiscal year ended March 31, 2023, and, in addition, is providing an additional business update to shareholders and other stakeholders.
- Medexus expects to deliver total revenue between $107 million and $108 million for fiscal year 2023, representing record annual revenue for Medexus and a year-over-year increase of at least 39.5%.
- As part of this record annual revenue, Medexus expects to deliver total revenue between $28 million and $28.5 million for fiscal Q4 2023, representing a year-over-year increase of at least 38.1%.
- IXINITY: Continuing positive trend in sales, with fiscal Q4 2023 reflecting the best quarter of fiscal year 2023 for new patient conversions on top of a stable, existing base of patients.
Retrieved on:
Wednesday, March 22, 2023
The product, which Medexus will submit for Health Canada approval later this year, has been widely used in other markets to treat fungal nail infections.
Key Points:
- The product, which Medexus will submit for Health Canada approval later this year, has been widely used in other markets to treat fungal nail infections.
- Medexus estimates the total value of the Canadian fungicides market to be C$88 million annually.
- *
“Terbinafine hydrochloride is an excellent strategic fit with our market leading product Rupall®.
- If and when approved by Health Canada, Medexus will pay Polichem a quarterly low double-digit percentage royalty on net sales of the product, inclusive of supply price.
TORONTO and CHICAGO, March 08, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; TSX: MDP.DB; OTCQX: MEDXF) today entered into a new senior secured credit agreement agented by BMO.
Key Points:
- TORONTO and CHICAGO, March 08, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; TSX: MDP.DB; OTCQX: MEDXF) today entered into a new senior secured credit agreement agented by BMO.
- The credit agreement provides for a US$35 million term loan facility and a US$3.5 million revolving loan facility for working capital.
- The term loan facility benefits from an additional US$20 million uncommitted accordion feature, which Medexus is confident will be available.
- The new BMO facilities will mature in March 2026, being three years from the date of the credit agreement.
TORONTO and CHICAGO, March 06, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce that company management will be participating in the 35th Annual Roth Conference from March 12 to 14, 2023.
Key Points:
- TORONTO and CHICAGO, March 06, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased to announce that company management will be participating in the 35th Annual Roth Conference from March 12 to 14, 2023.
- Ken d’Entremont, Medexus’s Chief Executive Officer, and Marcel Konrad, Medexus’s Chief Financial Officer, will present at a webcast fireside chat interview on March 14, 2023 at 1:00 PM Pacific time (4:00 PM Eastern time) and will be available for in-person one-on-one meetings throughout the conference.
- A live and recorded webcast of the Medexus presentation will be available on the Investors—News & Events section of Medexus’s corporate website or at the following link:
To learn more about this year’s event and to submit a registration request, visit the following link:
Retrieved on:
Wednesday, February 8, 2023
Marketing,
MBA,
SEDAR,
Federal Court of Canada,
Roberto Menassi,
TSX,
IQVIA,
Webcast,
Federal court,
Calendar,
Patient,
Patent,
Adjustment,
MAT,
Investment,
Growth,
PAP,
Research,
Pharmaceutical industry,
Video game,
Security (finance),
Risk management,
Internet service provider TORONTO and CHICAGO, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company’s third fiscal quarter ended December 31, 2022 (the company’s fiscal Q3 2023). All dollar amounts in this press release are in United States dollars unless specified otherwise.
Key Points:
- Record total revenue of $28.7 million, a year-over-year increase of 35%, and a quarter-over-quarter increase of 4%.
- Record Adjusted EBITDA* of $5.2 million, a year-over-year improvement of $3.3 million and a quarter-over-quarter increase of $1.0 million.
- Cash and cash equivalents of $9.3 million (with $10.1 million of total available liquidity) at end of fiscal Q3 2023.
- Medexus will host a conference call at 8:00 AM Eastern Time on Thursday, February 9, 2023, to discuss the company’s operating and financial results and corporate updates for fiscal Q3 2023.
TORONTO and CHICAGO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) is pleased to welcome Harmony P. Garges MD MPH, Chief Medical Officer of ViiV Healthcare, and Menassie Taddese MBA, former executive at Pfizer and Viatris, to the Medexus board of directors.
Key Points:
- Appointments bolster Medexus board’s medical and financial expertise, particularly in the United States
TORONTO and CHICAGO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) is pleased to welcome Harmony P. Garges MD MPH, Chief Medical Officer of ViiV Healthcare, and Menassie Taddese MBA, former executive at Pfizer and Viatris, to the Medexus board of directors.
- “We are very pleased to welcome Harmony and Menassie, two experienced professionals whose skills, experience, and expertise will serve to diversify and supplement those of the current members of our board,” commented Benoit Gravel, Chair of the Compensation, Corporate Governance, and Nominating Committee of the Board of Directors.
- Ken d’Entremont, Chief Executive Officer of Medexus, added, “We are thrilled to have Harmony and Menassie join our board.
- For more information about the Medexus board of directors, see the Governance section of Medexus’s corporate website.
Retrieved on:
Wednesday, February 1, 2023
Public,
RAMQ,
TSX,
Caregiver,
Cerebral palsy,
Government,
Hospital,
Hypersalivation,
Dysphagia,
Patient,
Partnership,
Health insurance,
Glycopyrronium bromide TORONTO and CHICAGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) wishes to inform investors that the company has reached an agreement with the provincial government of Quebec for government-sponsored coverage of Cuvposa (glycopyrrolate oral solution 1mg/5mL).
Key Points:
- TORONTO and CHICAGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) wishes to inform investors that the company has reached an agreement with the provincial government of Quebec for government-sponsored coverage of Cuvposa (glycopyrrolate oral solution 1mg/5mL).
- Cuvposa will be listed for public reimbursement on the Public Prescription Drug Insurance Plan of the Régime de l’Assurance Maladie du Québec, or RAMQ, starting February 1, 2023.
- Cuvposa is indicated in Canada to reduce chronic severe drooling in pediatric patients 3 to 18 years of age with neurologic conditions associated with problem drooling, such as cerebral palsy.
- “We are therefore proud to make Cuvposa available to more patients in Quebec through this new partnership with the Quebec government.
Retrieved on:
Tuesday, January 31, 2023
TORONTO and CHICAGO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 9, 2023 to discuss Medexus’s results for its third fiscal quarter ended December 31, 2022.
Key Points:
- TORONTO and CHICAGO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 9, 2023 to discuss Medexus’s results for its third fiscal quarter ended December 31, 2022.
- Medexus expects to file its financial statements and MD&A after markets close on February 8, 2023.
- To participate in the call, please dial the following numbers:
877-545-0523 (toll-free) for Canadian and U.S. callers
A live webcast of the call will be available on the Investors—News & Events—IR Calendar section of Medexus’s corporate website or at the following link:
A replay of the call will be available approximately one hour following the end of the call through Thursday, February 16, 2023.
- To access the replay, please dial the following numbers –
877-481-4010 for Canadian and U.S. callers
A replay of the webcast will be available on the Investors—News & Events—IR Calendar section of Medexus’s corporate website until Friday, February 9, 2024.
Retrieved on:
Thursday, January 12, 2023
TSX,
FDA,
Maintenance,
NDA,
Marketing,
Food,
Patient,
Clinical trial,
Video game,
Pharmaceutical industry,
Fine chemical,
Medac TORONTO and CHICAGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce preliminary estimates of the company’s revenue results for the fiscal quarter ended December 31, 2022 (the company’s fiscal Q3 2023) and provide additional business updates to shareholders and other stakeholders.
Key Points:
- TORONTO and CHICAGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce preliminary estimates of the company’s revenue results for the fiscal quarter ended December 31, 2022 (the company’s fiscal Q3 2023) and provide additional business updates to shareholders and other stakeholders.
- Medexus expects to deliver total revenue between $28.5 million and $29.0 million in fiscal Q3 2023.
- This will represent another record quarter of revenue for Medexus, and a year-over-year increase of at least 34% and a quarter-over-quarter increase of at least 3%.
- Primary drivers for the most recent quarter’s improved revenue performance were increases in net sales across Medexus’s portfolio.
